<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806633</url>
  </required_header>
  <id_info>
    <org_study_id>2663</org_study_id>
    <nct_id>NCT04806633</nct_id>
  </id_info>
  <brief_title>Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention</brief_title>
  <official_title>Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.Gennimatas General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>2nd Department of Cardiology, &quot;Attikon&quot; University Hospital, National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G.Gennimatas General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left heart catheterization and percutaneous coronary intervention (PCI) has become a useful&#xD;
      tool in interventional cardiology, in which iodinated contrast media is used. Although the&#xD;
      use of iodinated contrast media (CM) is considered to be safe in patients with normal renal&#xD;
      function, it is risky in patients with known chronic renal insufficiency (CKD) and diabetes&#xD;
      mellitus. Contrast induced nephropathy (CIN) remains one of the most leading causes of in&#xD;
      hospital acute kidney injury (AKI), affecting morbidity and mortality. There are various&#xD;
      mechanisms through which CM develop their nephrotoxic effects, including renal&#xD;
      vasoconstriction and medullary hypoxia, tubular cell toxicity and reactive oxygen species&#xD;
      formation.&#xD;
&#xD;
      Inhibitors of type 2 sodium- glucose co-transporter (SGLT2i) is a relatively recent addition&#xD;
      to the array of anti-diabetic agents, becoming part of everyday clinical practice. However,&#xD;
      although SGLT2i were first used solely as antidiabetics because of their glycosuric effect,&#xD;
      further research demonstrated that these drugs may independently reduce cardiovascular&#xD;
      events, especially in patients with heart failure, a benefit that was consistent among&#xD;
      diabetic and non-diabetic patients. Moreover, pleiotropic effects have been observed,&#xD;
      including a reno-protective action. In addition to the effects mediated by intrarenal&#xD;
      hemodynamic changes, SGLT2-i also have direct anti-inflammatory and antifibrotic&#xD;
      nephroprotective effects. Indeed, SGLT2-i suppress the production of reactive oxygen species,&#xD;
      lessening glomerulosclerosis and tubulo-interstitial fibrosis.&#xD;
&#xD;
      These findings suggest that the use of SGLT2i could offer benefit by reducing/ preventing the&#xD;
      nephrotoxic effects of contrast media leading to the assumption that the use of these drugs&#xD;
      could prevent the incidence nephropathy after cardiac catheterization and percutaneous&#xD;
      coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of incidence of acute kidney injury (AKI) between the two study arms</measure>
    <time_frame>1 month</time_frame>
    <description>AKI is defined defined as an absolute creatinine level increase of at least 0.3 mg/dL (≥26.5 μmol/L) or at least 1.5-fold from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of at least Stage 2 AKI (according to the KDIGO criteria), i.e. Increase in sCR&gt;2.0-fold from baseline.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence (cases per 100 patient-years) of hypoglycemia in both arms Any episode of hypoglycemia defined as serum glucose 60&lt; mg/dl associated with symptoms of hypoglycemia.</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence (cases per 100 patient-years)of diabetic ketoacidosis.</measure>
    <time_frame>1 month</time_frame>
    <description>Any episode of metabolic acidosis (pH&lt;7.3) with decreased serum bicarbonate (&lt;18mEq/ml) and</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence (cases per 100 patient-years)of lower urinary tract infections</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of all cause mortality between the two groups</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1722</enrollment>
  <condition>Left Cardiac Catheterization</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Sodium-glucose Co-transporter 2 Inhibitors</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will be randomized to receive dapagliflozin following cardiac catheterization and PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who will be randomized to receive placebo following cardiac catheterization and PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 5mg</intervention_name>
    <description>Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomized in this arm will receive placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 [CKD stage G1-G3]&#xD;
&#xD;
          -  Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic&#xD;
             patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Participation in other intervention study&#xD;
&#xD;
          -  Class I or equivalent indication for treatment with a SGLT2 inhibitor&#xD;
&#xD;
          -  Pregnancy or willing of pregnancy during the follow up period&#xD;
&#xD;
          -  Active urogenital infection&#xD;
&#xD;
          -  Diabetes mellitus type 1&#xD;
&#xD;
          -  History of diabetic ketoacidosis&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  eGFR &lt; 29 ml/min/1.73m2&#xD;
&#xD;
               -  Patients with an indication for SGLT2 inhibitor will be included in a prospective&#xD;
                  registry. Their treatment will be determined by their attending physicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spyridon Deftereos, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Spyridon Deftereos, Prof.</last_name>
    <email>spdeftereos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georgios Giannopoulos, Prof.</last_name>
    <phone>+302107768132</phone>
    <email>georgios.giannopolous@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Department, Athens General Hospital &quot;G. Gennimatas&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece.</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Aurelio A, Durante A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014;128(1):62-72. doi: 10.1159/000358042. Epub 2014 Feb 18. Review.</citation>
    <PMID>24557146</PMID>
  </results_reference>
  <results_reference>
    <citation>Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Kaunas). 2019 Jun 11;55(6). pii: E268. doi: 10.3390/medicina55060268. Review.</citation>
    <PMID>31212638</PMID>
  </results_reference>
  <results_reference>
    <citation>McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016 Sep 27;68(13):1465-1473. doi: 10.1016/j.jacc.2016.05.099. Review.</citation>
    <PMID>27659469</PMID>
  </results_reference>
  <results_reference>
    <citation>Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70. Epub 2005 Sep 21.</citation>
    <PMID>16177006</PMID>
  </results_reference>
  <results_reference>
    <citation>Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.</citation>
    <PMID>32970396</PMID>
  </results_reference>
  <results_reference>
    <citation>Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation. Horm Metab Res. 2016 Mar;48(3):191-5. doi: 10.1055/s-0035-1555791. Epub 2015 Jul 9.</citation>
    <PMID>26158396</PMID>
  </results_reference>
  <results_reference>
    <citation>Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.</citation>
    <PMID>27440829</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G.Gennimatas General Hospital</investigator_affiliation>
    <investigator_full_name>Spyridon Deftereos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>dapaglifozin</keyword>
  <keyword>iodinated contrast media</keyword>
  <keyword>Sodium-glucose Co-transporter 2 Inhibitors</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

